IP Library Granted Patent US 12673216
Granted Patent B2
US 12673216 · App. 18/640,609 · Granted Jul 7, 2026

Internal ultraviolet therapy

Inventors: Ali Rezaie (Beverly Hills, CA); Mark Pimentel (Los Angeles, CA); Gil Y. Melmed (Los Angeles, CA); Ruchi Mathur (Los Angeles, CA); Gabriela Guimaraes Sousa Leite (Porter Ranch, CA)
Assignee: Cedars-Sinai Medical Center
A61N5/0624A61N5/0603A61N2005/0604A61N2005/0651A61N2005/0661
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673216
App. No.
18/640,609
Granted
Jul 7, 2026
Kind
B2
Abstract

A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Claims (23)

1 . A method of treating a patient for an infectious condition and/or an inflammatory condition inside the patient's body, the method comprising:

inserting a delivery tube inside an intra-corporeal patient cavity; and

emitting UV-A light in the range of 335-350 nm from at least one ultraviolet (UV) light source connected to the delivery tube,

wherein the at least one UV-light source is configured to emit the UV-A light at wavelengths in the range of 335-350 nm outward from the delivery tube for a threshold duration and a threshold intensity.

2 . The method of claim 1 , wherein the UV-A light at wavelengths in the range of 335-350 nm targets an infectious condition inside the patient's body without causing UV induced DNA damage to the patient.

3 . The method of claim 1 , wherein the UV-A light at wavelengths in the range of 335-350 nm targets an infectious condition in an organ, tissue or cell inside the patient's body without causing UV induced DNA damage to the organ, tissue, or cell of the patient.

4 . The method of claim 1 , wherein the at least one UV light source is multiple UV light sources.

5 . The method of claim 1 , wherein the at least one UV light source is a light emitting diode (LED).

6 . The method of claim 1 , wherein the at least one UV light source is a string of LED light sources.

7 . The method of claim 1 , wherein the delivery tube comprises a proximal end configured for insertion into the intra-corporeal cavity of the patient and a distal end configured for maneuvering the delivery tube.

8 . The method of claim 1 , wherein the delivery tube is a catheter.

9 . The method of claim 1 , wherein the intra-corporeal cavity is a rectum, vagina, artery, urethra, urinary tract, bladder, sigmoid, colon, anus, mouth, esophagus, gastroesophageal junction, or stomach.

10 . The method of claim 1 , wherein the infectious condition is selected from the group consisting of a bacterial infection, a viral infection, a fungal infection, and combinations thereof.

11 . The method of claim 1 , wherein the infectious condition is pneumonia.

12 . The method of claim 1 , wherein the threshold duration comprises at least 20 minutes.

13 . The method of claim 1 , wherein the threshold intensity comprises at least 13, 15, or 18 W/m 2 .

14 . The method of claim 1 , wherein the threshold intensity comprises an intensity of at least any one of 1,000 microWatt/cm 2 , 1,100 microWatt/cm 2 , 2,000 microWatt/cm 2 , 2,100 microWatt/cm 2 , 2,200 microWatt/cm 2 , 2,300 microWatt/cm 2 , 2,400 microWatt/cm 2 , 2,500 microWatt/cm 2 , 2,600 microWatt/cm 2 , 2,700 microWatt/cm 2 , 2,800 microWatt/cm 2 , 2,900 microWatt/cm 2 , or 3,000 microWatt/cm 2 .

15 . The method of claim 1 , wherein the delivery tube is inserted inside an endotracheal tube, or wherein the delivery tube is inserted inside an endotracheal tube while suctioning the endotracheal tube.

16 . The method of claim 1 , wherein the at least one UV light source is positioned at a distance from target cells, the distance based on the threshold intensity and pathogen causing the infectious condition.

17 . The method of claim 16 , wherein the distance is between 0 and 4 centimeters.

18 . The method of claim 1 , wherein the infectious condition is caused by Escherichia coli, Clostridium difficile , and/or Candida albicans , and the UV-A light emission reduces growth of Escherichia coli, Clostridium difficile and Candida albicans.

19 . The method of claim 18 , wherein UV-A light exposure time is 20, 40, or 60 minutes, intensity ranging 1300 μW/cm 2 to 3500 μW/cm 2 .

20 . The method of claim 1 , wherein the infections condition is caused by Coronavirus, and the UV-A light emission in endotracheal (ET) tube kills Coronavirus.